\-\ Texto\\:\\ \ \(0\)\
\-\ psa\\ levels\\:\\ \\ increasing\\ levels\\ of\\ psa\\ from\\ 15\\.81\\ to\\ 96\\.91\\ during\\ a\\ six\\ month\\ period\\ of\\ time\ \(0\)\
\-\ analgesics\\ for\\ treatment\\ of\\ bone\\ pain\ \(0\)\
\-\ antineoplastic\\ therapy\\ with\\ androgen\\ deprivation\\.\ \(0\)\
\-\ radiation\\ therapy\ \(165\)\
\-\ multiple\\ sclerotic\\ lesions\\ involving\\ the\\ vertebrae\\ and\\ the\\ iliac\\ bones\\ consistent\\ with\\ metastases\\ from\\ prostate\\ cancer\ \(0\)\
\-\ bone\\ metastasis\\ from\\ prostate\\ cancer\\.\ \(0\)\
\-\ bone\\ metastases\\ most\\ commonly\\ from\\ prostate\ \(0\)\
\-\ sclerotic\\ paget\\'s\\-\\ less\\ likely\ \(0\)\
\-\ infection\\,\\ such\\ as\\ tuberculosis\\,\\ unusual\\ without\\ joint\\ space\\ involvement\ \(0\)\
\-\ patient\\ is\\ a\\ 60\\ y\\/o\\ wm\\ with\\ history\\ of\\ prostate\\ ca\\,\\ s\\/p\\ radical\\ prostatectomy\\ with\\ regional\\ lymph\\ node\\ resection\\.\\ \\ patient\\ subsequently\\ underwent\\ 2\\ courses\\ of\\ chemotherapy\\ treatments\\ with\\ response\\.\\ \\ with\\ 3\\ months\\ the\\ patient\\ developed\\ bone\\ metastases\\ from\\ his\\ prostatic\\ carcinoma\\.\\ he\\ is\\ currently\\ enrolled\\ in\\ a\\ trial\\ therapy\\,\\ which\\ requires\\ interval\\ follow\\-up\\ diagnostic\\ imaging\\ study\\ to\\ evaluate\\ response\\ to\\ therapy\\.\ \(0\)\
\-\ metastatic\\ prostate\\ cancer\\ is\\ usually\\ spread\\ hematogenously\\;\\.\\ metastases\\ to\\ bone\\ are\\ the\\ most\\ common\\ metastasis\\ with\\ prostate\\ cancer\\.\\ \\ the\\ proposed\\ hypothesis\\ for\\ this\\ pattern\\ of\\ spread\\ of\\ metastasis\\ is\\ retrograde\\ spread\\ to\\ the\\ axial\\ skeleton\\ \\(pelvis\\ and\\ vertebrae\\)\\ via\\ batson\\â\\€\\™s\\ venous\\ plexus\\,\\ which\\ is\\ a\\ valveless\\ venous\\ plexus\\ of\\ the\\ spine\\ and\\ paraspinal\\ region\\ with\\ communication\\ between\\ the\\ pelvic\\ and\\ vertebral\\ venous\\ systems\\,\\ femoral\\ and\\ iliac\\ veins\\,\\ inferior\\ and\\ superior\\ vena\\ cava\\,\\ and\\ other\\ veins\\.\\ this\\ system\\ may\\ be\\ important\\ for\\ hematogenous\\ spread\\ of\\ either\\ metastases\\ or\\ of\\ microorganisms\\ in\\ spinal\\ infection\\.\\ \\ prostatic\\ metastases\\ are\\ usually\\ osteoblastic\\ as\\ shown\\ on\\ radiographs\\ and\\ on\\ ct\\ images\\.\\ however\\,\\ scintigraphy\\ \\(bone\\ scans\\)\\ are\\ useful\\ for\\ detecting\\ early\\ metastases\\ several\\ weeks\\ or\\ months\\ before\\ the\\ radiographs\\ become\\ abnormal\\.\\ \\ \\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ increase\\ in\\ public\\ awareness\\ of\\ prostate\\ cancer\\ and\\ in\\ the\\ use\\ of\\ psa\\ to\\ screen\\ for\\ the\\ disease\\ has\\ led\\ to\\ early\\ diagnosis\\ and\\ treatment\\ of\\ prostate\\ cancer\\.prior\\ to\\ 1991\\,\\ greater\\ than\\ 30\\%\\ of\\ patients\\ developed\\ distant\\ metastases\\ currently\\ approximately\\ 6\\%\\ have\\ metastases\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prostate\\:\\ 0\\.10936993505904682\ \(0\)\
\-\ metastases\\:\\ 0\\.09896563870598452\ \(0\)\
\-\ psa\\:\\ 0\\.05405697361364713\ \(0\)\
\-\ spread\\:\\ 0\\.049799845745087695\ \(0\)\
\-\ cancer\\:\\ 0\\.042306705788625984\ \(0\)\
\-\ bone\\:\\ 0\\.03837532556855187\ \(0\)\
\-\ prostatic\\:\\ 0\\.03720759695392313\ \(0\)\
\-\ vertebrae\\:\\ 0\\.029660832083469105\ \(0\)\
\-\ metastasis\\:\\ 0\\.028904343309939094\ \(0\)\
\-\ venous\\:\\ 0\\.028028183299311407\ \(0\)\
\-\ therapy\\:\\ 0\\.02752579272579052\ \(0\)\
\-\ 15\\.81\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ 96\\.91\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ \\-analgesics\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ \\-antineoplastic\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ paget\\'s\\-\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ valveless\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ cancer\\.prior\\:\\ 0\\.02655276633724849\ \(0\)\
\-\ response\\:\\ 0\\.025800716450682184\ \(0\)\
\-\ iliac\\:\\ 0\\.025672539351602155\ \(0\)\
\-\ plexus\\:\\ 0\\.02501252608346043\ \(0\)\
\-\ veins\\:\\ 0\\.02462729280273589\ \(0\)\
\-\ \\-radiation\\:\\ 0\\.024464973624718535\ \(0\)\
\-\ deprivation\\:\\ 0\\.023243693178609606\ \(0\)\
\-\ batson\\:\\ 0\\.023243693178609606\ \(0\)\
\-\ microorganisms\\:\\ 0\\.023243693178609606\ \(0\)\
\-\ sclerotic\\:\\ 0\\.023042685766191336\ \(0\)\
\-\ prostatectomy\\:\\ 0\\.022377180912188578\ \(0\)\
\-\ hematogenously\\:\\ 0\\.022377180912188578\ \(0\)\
\-\ androgen\\:\\ 0\\.02170506178172409\ \(0\)\
\-\ enrolled\\:\\ 0\\.02170506178172409\ \(0\)\
\-\ public\\:\\ 0\\.02170506178172409\ \(0\)\
\-\ levels\\:\\ 0\\.02124850236910821\ \(0\)\
\-\ currently\\:\\ 0\\.020398631295253357\ \(0\)\
\-\ developed\\:\\ 0\\.019819671595389846\ \(0\)\
\-\ hypothesis\\:\\ 0\\.019617269069194136\ \(0\)\
\-\ from\\:\\ 0\\.01907282700533452\ \(0\)\
\-\ awareness\\:\\ 0\\.018827015260557113\ \(0\)\
\-\ early\\:\\ 0\\.018826258853267698\ \(0\)\
\-\ 1991\\:\\ 0\\.017846827307440766\ \(0\)\
\-\ courses\\:\\ 0\\.017108506650714908\ \(0\)\
\-\ proposed\\:\\ 0\\.016980315041019736\ \(0\)\
\-\ detecting\\:\\ 0\\.016980315041019736\ \(0\)\
\-\ hematogenous\\:\\ 0\\.016625546861331837\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.01651600576443161\ \(0\)\
\-\ wm\\:\\ 0\\.01630819591055525\ \(0\)\
\-\ regional\\:\\ 0\\.01630819591055525\ \(0\)\
\-\ radiographs\\:\\ 0\\.016302836392783935\ \(0\)\
\-\ trial\\:\\ 0\\.016209431383979976\ \(0\)\
\-\ radical\\:\\ 0\\.016113802774598708\ \(0\)\
\-\ skeleton\\:\\ 0\\.01575903459491081\ \(0\)\
\-\ usually\\:\\ 0\\.015632097914859994\ \(0\)\
\-\ led\\:\\ 0\\.015596181518795521\ \(0\)\
\-\ retrograde\\:\\ 0\\.015441683644134223\ \(0\)\
\-\ communication\\:\\ 0\\.015086915464446323\ \(0\)\
\-\ distant\\:\\ 0\\.01502071393818495\ \(0\)\
\-\ infection\\:\\ 0\\.01496395526549884\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.014955936211615783\ \(0\)\
\-\ screen\\:\\ 0\\.014955936211615783\ \(0\)\
\-\ treatments\\:\\ 0\\.014892522328489782\ \(0\)\
\-\ months\\:\\ 0\\.014059887317410045\ \(0\)\
\-\ paraspinal\\:\\ 0\\.013756093921437167\ \(0\)\
\-\ requires\\:\\ 0\\.013671241882380853\ \(0\)\
\-\ systems\\:\\ 0\\.013671241882380853\ \(0\)\
\-\ vena\\:\\ 0\\.013629695731379843\ \(0\)\
\-\ cava\\:\\ 0\\.013548284067560808\ \(0\)\
\-\ useful\\:\\ 0\\.013430149389388274\ \(0\)\
\-\ six\\:\\ 0\\.01265180092507602\ \(0\)\
\-\ interval\\:\\ 0\\.012622125333380202\ \(0\)\
\-\ unusual\\:\\ 0\\.012449961436271924\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.012260802095190508\ \(0\)\
\-\ become\\:\\ 0\\.012260802095190508\ \(0\)\
\-\ period\\:\\ 0\\.012033845958920064\ \(0\)\
\-\ \\%\\:\\ 0\\.012007958032204866\ \(0\)\
\-\ ca\\:\\ 0\\.011985652159683797\ \(0\)\
\-\ scans\\:\\ 0\\.011985652159683797\ \(0\)\
\-\ most\\:\\ 0\\.011884549046554676\ \(0\)\
\-\ node\\:\\ 0\\.011777842305807437\ \(0\)\
\-\ subsequently\\:\\ 0\\.011668301208907212\ \(0\)\
\-\ important\\:\\ 0\\.011562604462487722\ \(0\)\
\-\ 60\\:\\ 0\\.011228680990162995\ \(0\)\
\-\ either\\:\\ 0\\.011210145250481134\ \(0\)\
\-\ via\\:\\ 0\\.01104826490106339\ \(0\)\
\-\ for\\:\\ 0\\.010980544407269806\ \(0\)\
\-\ before\\:\\ 0\\.010894642749098413\ \(0\)\
\-\ bones\\:\\ 0\\.010861542985316499\ \(0\)\
\-\ s\\/p\\:\\ 0\\.010796415081662385\ \(0\)\
\-\ increase\\:\\ 0\\.010796415081662385\ \(0\)\
\-\ pelvic\\:\\ 0\\.010564008212546064\ \(0\)\
\-\ increasing\\:\\ 0\\.010549133870255153\ \(0\)\
\-\ are\\:\\ 0\\.010525968727677124\ \(0\)\
\-\ treatment\\:\\ 0\\.010419379274704139\ \(0\)\
\-\ evaluate\\:\\ 0\\.010404295958605642\ \(0\)\
\-\ lymph\\:\\ 0\\.010390187978748936\ \(0\)\
\-\ shown\\:\\ 0\\.010320622572740957\ \(0\)\
\-\ to\\:\\ 0\\.010290797793806898\ \(0\)\
\-\ diagnostic\\:\\ 0\\.010199315647626678\ \(0\)\
\-\ vertebral\\:\\ 0\\.010186133796422466\ \(0\)\
\-\ use\\:\\ 0\\.010173009382660551\ \(0\)\
\-\ system\\:\\ 0\\.010133975814460235\ \(0\)\
\-\ 30\\:\\ 0\\.00989785944715384\ \(0\)\
\-\ pattern\\:\\ 0\\.009838681744190598\ \(0\)\
\-\ femoral\\:\\ 0\\.009792162700734353\ \(0\)\
\-\ commonly\\:\\ 0\\.0097124441067941\ \(0\)\
\-\ greater\\:\\ 0\\.009667820354429221\ \(0\)\
\-\ which\\:\\ 0\\.009609304742424992\ \(0\)\
\-\ involvement\\:\\ 0\\.009433550170565713\ \(0\)\
\-\ pelvis\\:\\ 0\\.00935268495961334\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.009225740316689353\ \(0\)\
\-\ spinal\\:\\ 0\\.009216193404757789\ \(0\)\
\-\ involving\\:\\ 0\\.009031347180732813\ \(0\)\
\-\ underwent\\:\\ 0\\.00883191576951271\ \(0\)\
\-\ inferior\\:\\ 0\\.008732880606503202\ \(0\)\
\-\ less\\:\\ 0\\.00871668676000808\ \(0\)\
\-\ space\\:\\ 0\\.008513725924929622\ \(0\)\
\-\ spine\\:\\ 0\\.008476215500016109\ \(0\)\
\-\ study\\:\\ 0\\.008468769147168553\ \(0\)\
\-\ is\\:\\ 0\\.008468234614227795\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.008373605395908862\ \(0\)\
\-\ joint\\:\\ 0\\.008323582093500245\ \(0\)\
\-\ several\\:\\ 0\\.00827437601121201\ \(0\)\
\-\ superior\\:\\ 0\\.008219107521247564\ \(0\)\
\-\ between\\:\\ 0\\.008158119085012783\ \(0\)\
\-\ \\,\\:\\ 0\\.008153917636062873\ \(0\)\
\-\ such\\:\\ 0\\.008046183101930279\ \(0\)\
\-\ resection\\:\\ 0\\.008026854384097044\ \(0\)\
\-\ approximately\\:\\ 0\\.00796330670649272\ \(0\)\
\-\ during\\:\\ 0\\.007876533885312675\ \(0\)\
\-\ as\\:\\ 0\\.007786611481289927\ \(0\)\
\-\ patient\\:\\ 0\\.007740288532376999\ \(0\)\
\-\ month\\:\\ 0\\.00772173054458015\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.00769285162543812\ \(0\)\
\-\ 6\\:\\ 0\\.007687108919803839\ \(0\)\
\-\ his\\:\\ 0\\.007418340444719675\ \(0\)\
\-\ s\\:\\ 0\\.007381830322634298\ \(0\)\
\-\ axial\\:\\ 0\\.007345757458035758\ \(0\)\
\-\ abnormal\\:\\ 0\\.007340639278056962\ \(0\)\
\-\ weeks\\:\\ 0\\.007305053484642014\ \(0\)\
\-\ carcinoma\\:\\ 0\\.007294962861493574\ \(0\)\
\-\ time\\:\\ 0\\.0072698832145762435\ \(0\)\
\-\ region\\:\\ 0\\.0072698832145762435\ \(0\)\
\-\ likely\\:\\ 0\\.007259909535950773\ \(0\)\
\-\ he\\:\\ 0\\.007181287174798252\ \(0\)\
\-\ however\\:\\ 0\\.007166771251798406\ \(0\)\
\-\ y\\/o\\:\\ 0\\.007128400692227833\ \(0\)\
\-\ lesions\\:\\ 0\\.006890242488987794\ \(0\)\
\-\ than\\:\\ 0\\.006744123056982753\ \(0\)\
\-\ common\\:\\ 0\\.006735744614326498\ \(0\)\
\-\ patients\\:\\ 0\\.0066613692751988736\ \(0\)\
\-\ metastatic\\:\\ 0\\.00647924519161473\ \(0\)\
\-\ consistent\\:\\ 0\\.006311139363949407\ \(0\)\
\-\ \\;\\:\\ 0\\.006100666230278897\ \(0\)\
\-\ without\\:\\ 0\\.006060280621560723\ \(0\)\
\-\ or\\:\\ 0\\.006033269572070527\ \(0\)\
\-\ imaging\\:\\ 0\\.006030342844745792\ \(0\)\
\-\ 3\\:\\ 0\\.0060270347189956015\ \(0\)\
\-\ other\\:\\ 0\\.005932646231031472\ \(0\)\
\-\ diagnosis\\:\\ 0\\.005910299189097651\ \(0\)\
\-\ this\\:\\ 0\\.005789983212735742\ \(0\)\
\-\ may\\:\\ 0\\.005645567376199169\ \(0\)\
\-\ have\\:\\ 0\\.005573608669774373\ \(0\)\
\-\ 2\\:\\ 0\\.005542483423224537\ \(0\)\
\-\ and\\:\\ 0\\.005421958003982484\ \(0\)\
\-\ multiple\\:\\ 0\\.00542110242011828\ \(0\)\
\-\ in\\:\\ 0\\.005077075061930783\ \(0\)\
\-\ the\\:\\ 0\\.004996962097721414\ \(0\)\
\-\ images\\:\\ 0\\.004937541843220946\ \(0\)\
\-\ of\\:\\ 0\\.004912810877023608\ \(0\)\
\-\ has\\:\\ 0\\.004833433646067102\ \(0\)\
\-\ a\\:\\ 0\\.004778310865284353\ \(0\)\
\-\ on\\:\\ 0\\.004360789231117036\ \(0\)\
\-\ \\(\\:\\ 0\\.004351576664119642\ \(0\)\
\-\ \\)\\:\\ 0\\.004298419832007862\ \(0\)\
\-\ disease\\:\\ 0\\.00420704078679429\ \(0\)\
\-\ be\\:\\ 0\\.003969146757060027\ \(0\)\
\-\ ct\\:\\ 0\\.003600312209012178\ \(0\)\
\-\ history\\:\\ 0\\.0035548630653827813\ \(0\)\
\-\ \\:\\:\\ 0\\.0034044422168393526\ \(0\)\
\-\ pain\\:\\ 0\\.0031433980949720926\ \(0\)\
\-\ with\\:\\ 0\\.002819377737105777\ \(0\)\
\-\ \\.\\:\\ 0\\.0013900420761009083\ \(0\)\
